Bioscrip Inc: (NASD: BIOS)

$13.86

0.18 (1.32%)

Volume 155,457

May 22 11:00 AM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		13.62 - 13.97
	
		52wk Low - High
		6.14 - 14.73
	
		Previous Close
		13.68
	
		Avg. Volume
		687,015
	
		Industry
		RETAIL-DRUG STR
	
		Market Cap
		780.24 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.74
	
		PE (Forward)
		58.21
	
		Current Year Est.
		0.23
	
		Quarterly Earnings ESP 
		-50.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Outperform
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		42 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            58.21
                        
                            PEG Ratio
                            3.06
                        
                            Current Year Est.
                            0.23
                        
                            Current Quarter Estimate
                            0.02
                        
                            Most Accurate Estimate
                            0.01
                        
                            Earnings ESP 
                            -50.00%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            0.05
                        
                            Expected Earnings Growth
                            19.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: specialty medication distribution and clinical management services, both nationally and community-based and pharmacy benefit management services.   
Full BIOS Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
BIOS Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.02	0.06	0.23	0.33
Number of Estimates	3	3	2	3
Low Estimate	0.00	0.04	0.21	0.20
High Estimate	0.04	0.09	0.26	NA
Year Ago EPS	-0.02	0.04	-0.01	0.23
EPS Growth	200.00%	58.33%	2,450.00%	41.84%

More BIOS Estimates

Average Earnings Estimates for BIOS

EPS Growth for BIOS

Industry Analysis

Name	Symbol	Previous Close
BIOSCRIP INC	BIOS	13.68
CHINA NEPSTAR	NPD	1.71
GNC HOLDINGS	GNC	45.78
HERBALIFE LTD	HLF	50.54
RITE AID CORP	RAD	2.89
AMERISOURCEBRGN	ABC	54.65
CARDINAL HEALTH	CAH	47.96
CVS CAREMARK CP	CVS	59.51
MCKESSON CORP	MCK	118.41
PHARMERICA CORP	PMC	14.19

Sector:Retail-Wholesale>> Industry:RETAIL-DRUG STR

COMPARE TICKER vs. Its Peers

Zacks Commentary

BIOS Misses Earnings Mark But Rev Tops

May 09, 2013

Sluggish Segments Sour CVS Earnings Beat

May 01, 2013

The Zacks Analyst Blog Highlights: Microsoft, VMware, Apple, Google and BioScrip

Apr 11, 2013

BioScrip Raised to Outperform

Apr 10, 2013

Zacks Rank #1 Addition for Thursday

Mar 14, 2013

BioScrip Beats; Avid FY13 Outlook

Mar 12, 2013

BioScrip Reaffirmed at Neutral

Feb 20, 2013

Still Neutral on Walgreens

Jan 21, 2013

More BIOS Zacks Commentary

Financials

EPS TTM	0.05
Sales	663
Net Income	59
Price/Earnings	273.60
Price/Book	2.71
Price/Cash Flow	58.47
Price/Sales	1.11

More BIOS Financials

News

BioScrip is Among the Companies in the Health Care Services Industry with the Best Relative Performance (BIOS, AIRM, BRLI, LH, DGX) - Financial News Network Online - News Corner

May 22, 2013

BioScrip reports higher Q1 net loss, reaffirms guidance for 2013 - Datamonitor

May 22, 2013

Amedisys has Relatively Underperformed its Peers in the Health Care Services Industry (AMED, HMSY, ESRX, DVA, BIOS) - Financial News Network Online - News Corner

May 21, 2013

Benzinga`s Top Initiations - Benzinga

May 21, 2013

BioScrip Bullish Moving Average Crossover Alert (BIOS) - Financial News Network Online - Moving Average Crossovers

May 21, 2013

Stock Investors Bid Up Shares of BioScrip, Up 2.7% - Financial News Network Online - Market Movers

May 21, 2013

UPDATE: Jefferies Initates Coverage on BioScrip With a Buy Rating on Likely EBITDA Growth - Benzinga

May 21, 2013

BioScrip Up 80.3% Since SmarTrend Uptrend Call (BIOS) - Comtex Smartrend(R)

May 20, 2013

See All News Stories on BIOS

Broker Recommendations

Current ABR	1.17
ABR (Last Week)	1.20
# of recs in ABR	6
Average Target Price	15.67
Industry Rank by ABR	42 out of 265
Rank in Industry	10 out of 11

More BIOS Broker Recommendations

Day Low - High	13.62 - 13.97
52wk Low - High	6.14 - 14.73
Previous Close	13.68
Avg. Volume	687,015
Industry	RETAIL-DRUG STR
Market Cap	780.24 M
Div - Yield	0.00 - 0.00
Beta	1.74
PE (Forward)	58.21
Current Year Est.	0.23
Quarterly Earnings ESP	-50.00%

PE (Forward)	58.21
PEG Ratio	3.06
Current Year Est.	0.23
Current Quarter Estimate	0.02
Most Accurate Estimate	0.01
Earnings ESP	-50.00%
Next Earnings Report Date	08-07-2013
EPS Last Year	0.05
Expected Earnings Growth	19.00%

Username: Password:

Remember me [?]

Bioscrip Inc: (NASD: BIOS)

$13.86

0.18 (1.32%)

Volume 155,457

May 22 11:00 AM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Retail-Wholesale>> Industry:RETAIL-DRUG STR

Zacks Commentary

Financials

News

Broker Recommendations